MedPath

Ibaraki ER Network Epilepsy Control Trial with LevetIracetam vs. FosphEnytoine

Phase 3
Conditions
status epilepticus
Registration Number
JPRN-jRCTs031190160
Lead Sponsor
Inoue Yoshiaki
Brief Summary

The efficacy of LEV was similar to that of FPHT for the treatment of adult SE following the administration of diazepam. Since it was associated with fewer serious adverse event, LEV is recommended as a second-line treatment for SE as an alternative to phenytoin/FPHT.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
176
Inclusion Criteria

status epilepticus with convulsion, who were transfered by ambulance
The difinition of status epilepticus is as follows; over 5 minutes of continuous seizures, or over 2 minutes discrete seizures between which there is incomplete recovery of consciousness over JCS II-30
exclude non-convulsive seizure

Exclusion Criteria

under 20 years old
patients who entried this study in the past
patients in whom informed consent can not be obtained from proxies (If proxies can not be found, the study is performed and the consent is obtained after action.
already intubated patients before treatment
allergy to fosphenytoin or levetiracetam
pregnancy
pseudo-seizure
medical doctor considered inapropriate

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
seizure stop within 30 min from start of study drugs administration
Secondary Outcome Measures
NameTimeMethod
seizure reccurence within 24 h<br>severe adverse events<br>intubation rate
© Copyright 2025. All Rights Reserved by MedPath